Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
Identifieur interne : 000144 ( Main/Exploration ); précédent : 000143; suivant : 000145Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
Auteurs : Katrina Wilcox Hagberg [États-Unis] ; Rebecca Persson [États-Unis] ; Catherine Vasilakis-Scaramozza [États-Unis] ; Steve Niemcryk [États-Unis] ; Michael Peng [États-Unis] ; Maria Paris [États-Unis] ; Anders Lindholm [États-Unis] ; Susan Jick [États-Unis]Source :
- Clinical Epidemiology [ 1179-1349 ] ; 2020.
Abstract
Psoriasis and psoriatic arthritis (PsA) are associated with an increased infection risk. In this cohort study of patients with treated psoriasis or PsA, we used MarketScan (2014–2018) to estimate rates of herpes zoster, hepatitis C (HepC) and tuberculosis (TB) with apremilast compared to other systemic treatments.
Patients were exposed from first apremilast [APR], DMARD, TNF-inhibitor [TNF], IL-inhibitor [IL], or corticosteroids [CS] prescription after March 21, 2014. Study exposures were APR, DMARDs only, TNF-only, IL-only, CS-only, DMARDs+CS, TNF+DMARDs and/or CS, IL+DMARDs and/or CS. Cases had treated herpes zoster, HepC, or TB event. We calculated incidence rates (IRs) [95% confidence intervals] per 1000 patient-years.
The study population included 131,604 patients. For herpes zoster (N=2271), IRs were highest for users of DMARDs+CS (12.5 [9.8–15.7]), CS-only (12.5 [10.4–14.1]), and TNF+DMARDs and/or CS (11.9 [10.6–13.4]), compared with DMARDs only (9.9 [8.7–11.2]). IRs were lowest for users of IL-only (6.7 [5.8–7.8]) and APR (7.0 [5.8–8.4]). IRs of HepC (N=150) and TB (N=81) were low and between-treatment differences were not significant.
Rates of herpes zoster varied by treatment: highest among those who received polytherapy, lowest in users of apremilast only. IRs for HepC and TB were low for all exposures.
Url:
DOI: 10.2147/CLEP.S239511
PubMed: 32104099
PubMed Central: 7024766
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000485
- to stream Pmc, to step Curation: 000485
- to stream Pmc, to step Checkpoint: 000135
- to stream Ncbi, to step Merge: 000F67
- to stream Ncbi, to step Curation: 000F67
- to stream Ncbi, to step Checkpoint: 000F67
- to stream Main, to step Merge: 000144
- to stream Main, to step Curation: 000144
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis</title><author><name sortKey="Hagberg, Katrina Wilcox" sort="Hagberg, Katrina Wilcox" uniqKey="Hagberg K" first="Katrina Wilcox" last="Hagberg">Katrina Wilcox Hagberg</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Boston Collaborative Drug Surveillance Program</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Persson, Rebecca" sort="Persson, Rebecca" uniqKey="Persson R" first="Rebecca" last="Persson">Rebecca Persson</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Boston Collaborative Drug Surveillance Program</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Vasilakis Scaramozza, Catherine" sort="Vasilakis Scaramozza, Catherine" uniqKey="Vasilakis Scaramozza C" first="Catherine" last="Vasilakis-Scaramozza">Catherine Vasilakis-Scaramozza</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Boston Collaborative Drug Surveillance Program</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Niemcryk, Steve" sort="Niemcryk, Steve" uniqKey="Niemcryk S" first="Steve" last="Niemcryk">Steve Niemcryk</name><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Celgene Corporation</institution>,<addr-line>Summit</addr-line>,<addr-line>NJ</addr-line><addr-line>07901</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Peng, Michael" sort="Peng, Michael" uniqKey="Peng M" first="Michael" last="Peng">Michael Peng</name><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Celgene Corporation</institution>,<addr-line>Summit</addr-line>,<addr-line>NJ</addr-line><addr-line>07901</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Paris, Maria" sort="Paris, Maria" uniqKey="Paris M" first="Maria" last="Paris">Maria Paris</name><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Celgene Corporation</institution>,<addr-line>Summit</addr-line>,<addr-line>NJ</addr-line><addr-line>07901</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Lindholm, Anders" sort="Lindholm, Anders" uniqKey="Lindholm A" first="Anders" last="Lindholm">Anders Lindholm</name><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Celgene Corporation</institution>,<addr-line>Summit</addr-line>,<addr-line>NJ</addr-line><addr-line>07901</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Jick, Susan" sort="Jick, Susan" uniqKey="Jick S" first="Susan" last="Jick">Susan Jick</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Boston Collaborative Drug Surveillance Program</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Boston University School of Public Health</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32104099</idno><idno type="pmc">7024766</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024766</idno><idno type="RBID">PMC:7024766</idno><idno type="doi">10.2147/CLEP.S239511</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000485</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000485</idno><idno type="wicri:Area/Pmc/Curation">000485</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000485</idno><idno type="wicri:Area/Pmc/Checkpoint">000135</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000135</idno><idno type="wicri:Area/Ncbi/Merge">000F67</idno><idno type="wicri:Area/Ncbi/Curation">000F67</idno><idno type="wicri:Area/Ncbi/Checkpoint">000F67</idno><idno type="wicri:Area/Main/Merge">000144</idno><idno type="wicri:Area/Main/Curation">000144</idno><idno type="wicri:Area/Main/Exploration">000144</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis</title><author><name sortKey="Hagberg, Katrina Wilcox" sort="Hagberg, Katrina Wilcox" uniqKey="Hagberg K" first="Katrina Wilcox" last="Hagberg">Katrina Wilcox Hagberg</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Boston Collaborative Drug Surveillance Program</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Persson, Rebecca" sort="Persson, Rebecca" uniqKey="Persson R" first="Rebecca" last="Persson">Rebecca Persson</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Boston Collaborative Drug Surveillance Program</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Vasilakis Scaramozza, Catherine" sort="Vasilakis Scaramozza, Catherine" uniqKey="Vasilakis Scaramozza C" first="Catherine" last="Vasilakis-Scaramozza">Catherine Vasilakis-Scaramozza</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Boston Collaborative Drug Surveillance Program</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Niemcryk, Steve" sort="Niemcryk, Steve" uniqKey="Niemcryk S" first="Steve" last="Niemcryk">Steve Niemcryk</name><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Celgene Corporation</institution>,<addr-line>Summit</addr-line>,<addr-line>NJ</addr-line><addr-line>07901</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Peng, Michael" sort="Peng, Michael" uniqKey="Peng M" first="Michael" last="Peng">Michael Peng</name><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Celgene Corporation</institution>,<addr-line>Summit</addr-line>,<addr-line>NJ</addr-line><addr-line>07901</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Paris, Maria" sort="Paris, Maria" uniqKey="Paris M" first="Maria" last="Paris">Maria Paris</name><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Celgene Corporation</institution>,<addr-line>Summit</addr-line>,<addr-line>NJ</addr-line><addr-line>07901</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Lindholm, Anders" sort="Lindholm, Anders" uniqKey="Lindholm A" first="Anders" last="Lindholm">Anders Lindholm</name><affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Celgene Corporation</institution>,<addr-line>Summit</addr-line>,<addr-line>NJ</addr-line><addr-line>07901</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author><author><name sortKey="Jick, Susan" sort="Jick, Susan" uniqKey="Jick S" first="Susan" last="Jick">Susan Jick</name><affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Boston Collaborative Drug Surveillance Program</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Boston University School of Public Health</institution>,<addr-line>Lexington</addr-line>,<addr-line>MA</addr-line><addr-line>02421</addr-line>,<country>USA</country></nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea># see nlm:aff country strict</wicri:regionArea></affiliation></author></analytic><series><title level="j">Clinical Epidemiology</title><idno type="eISSN">1179-1349</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec id="S2001"><title>Purpose</title><p>Psoriasis and psoriatic arthritis (PsA) are associated with an increased infection risk. In this cohort study of patients with treated psoriasis or PsA, we used MarketScan (2014–2018) to estimate rates of herpes zoster, hepatitis C (HepC) and tuberculosis (TB) with apremilast compared to other systemic treatments.</p></sec><sec id="S2002"><title>Materials and Methods</title><p>Patients were exposed from first apremilast [APR], DMARD, TNF-inhibitor [TNF], IL-inhibitor [IL], or corticosteroids [CS] prescription after March 21, 2014. Study exposures were APR, DMARDs only, TNF-only, IL-only, CS-only, DMARDs+CS, TNF+DMARDs and/or CS, IL+DMARDs and/or CS. Cases had treated herpes zoster, HepC, or TB event. We calculated incidence rates (IRs) [95% confidence intervals] per 1000 patient-years.</p></sec><sec id="S2003"><title>Results</title><p>The study population included 131,604 patients. For herpes zoster (N=2271), IRs were highest for users of DMARDs+CS (12.5 [9.8–15.7]), CS-only (12.5 [10.4–14.1]), and TNF+DMARDs and/or CS (11.9 [10.6–13.4]), compared with DMARDs only (9.9 [8.7–11.2]). IRs were lowest for users of IL-only (6.7 [5.8–7.8]) and APR (7.0 [5.8–8.4]). IRs of HepC (N=150) and TB (N=81) were low and between-treatment differences were not significant.</p></sec><sec id="S2004"><title>Conclusion</title><p>Rates of herpes zoster varied by treatment: highest among those who received polytherapy, lowest in users of apremilast only. IRs for HepC and TB were low for all exposures.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Hagberg, Katrina Wilcox" sort="Hagberg, Katrina Wilcox" uniqKey="Hagberg K" first="Katrina Wilcox" last="Hagberg">Katrina Wilcox Hagberg</name></noRegion><name sortKey="Jick, Susan" sort="Jick, Susan" uniqKey="Jick S" first="Susan" last="Jick">Susan Jick</name><name sortKey="Jick, Susan" sort="Jick, Susan" uniqKey="Jick S" first="Susan" last="Jick">Susan Jick</name><name sortKey="Lindholm, Anders" sort="Lindholm, Anders" uniqKey="Lindholm A" first="Anders" last="Lindholm">Anders Lindholm</name><name sortKey="Niemcryk, Steve" sort="Niemcryk, Steve" uniqKey="Niemcryk S" first="Steve" last="Niemcryk">Steve Niemcryk</name><name sortKey="Paris, Maria" sort="Paris, Maria" uniqKey="Paris M" first="Maria" last="Paris">Maria Paris</name><name sortKey="Peng, Michael" sort="Peng, Michael" uniqKey="Peng M" first="Michael" last="Peng">Michael Peng</name><name sortKey="Persson, Rebecca" sort="Persson, Rebecca" uniqKey="Persson R" first="Rebecca" last="Persson">Rebecca Persson</name><name sortKey="Vasilakis Scaramozza, Catherine" sort="Vasilakis Scaramozza, Catherine" uniqKey="Vasilakis Scaramozza C" first="Catherine" last="Vasilakis-Scaramozza">Catherine Vasilakis-Scaramozza</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000144 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000144 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:7024766
|texte= Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32104099" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |